Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.57 |
| ▸ | HTR1A | P08908 | 4/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | HTR2B | P41595 | 3/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.57 |
| ▸ | HTR1D | P28221 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | HTR1E | P28566 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | HTR5A | P47898 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.57 |
| ▸ | HTR3B | O95264 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HTR1F | P30939 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075720 | 0.87 | KMT2A (0.72) | KMT2AMTNR1AHTR1AMTNR1BCYP2D6 | |
| SCHEMBL5085972 | 0.82 | KMT2A (0.65) | KMT2AMTNR1AHTR1AMTNR1BCYP2D6 | |
| SCHEMBL5085568 | 0.82 | KMT2A (0.65) | KMT2AMTNR1AHTR1AMTNR1BCYP2D6 | |
| SCHEMBL14639277 | 0.80 | MTNR1A (0.64) | MTNR1AMTNR1BHTR2BHTR2AHTR2C | |
| SCHEMBL5144423 | 0.79 | KMT2A (0.74) | KMT2AMTNR1AHTR1AMTNR1BCYP2D6 | |
| SCHEMBL466333 | 0.79 | KMT2A (0.70) | KMT2AMTNR1AHTR1AMTNR1BCYP2D6 | |
| SCHEMBL5227242 | 0.78 | KMT2A (0.69) | KMT2AMTNR1AHTR1AMTNR1BCYP2D6 | |
| SCHEMBL16058705 | 0.78 | KMT2A (0.69) | KMT2AMTNR1AHTR1AMTNR1BCYP2D6 | |
| SCHEMBL28414663 | 0.78 | KMT2A (0.69) | KMT2AMTNR1AHTR1AMTNR1BCYP2D6 | |
| SCHEMBL5146979 | 0.76 | KMT2A (0.66) | KMT2AMTNR1AHTR1AMTNR1BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709730-A1 | TREATMENT AND PROGNOSIS OF CANCER | Western Connecticut Health Network, Inc. (US) | 2014-03-26 | — | — | EP | claimed |
| US-20120295932-A1 | METHOD FOR THE TREATMENT OF CANCER | Western Connecticut Health Network, Inc. (US) | 2012-11-22 | — | — | US | claimed |
| WO-2012158358-A1 | TREATMENT AND PROGNOSIS OF CANCER | Western Connecticut Health Network, Inc. (US) | 2012-11-22 | — | — | WO | claimed |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230017359-A1 | METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| EP-4071473-A1 | METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION | Ascentawits Pharmaceuticals, Ltd. (CN) | 2022-10-12 | — | — | EP | disclosed |
| US-11215617-B2 | Treatment of metastatic prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3062808-B1 | TREATMENT OF METASTATIC PROSTATE CANCER | UNIV CALIFORNIA (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2021-08-19 | — | — | US | disclosed |
| WO-2021110085-A1 | METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION | 深圳艾欣达伟医药科技有限公司 | 2021-06-10 | — | — | WO | disclosed |
| US-20200041516-A1 | TREATMENT OF METASTATIC PROSTATE CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-02-06 | — | — | US | disclosed |
| US-9346803-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| WO-2015065919-A1 | TREATMENT OF METASTATIC PROSTATE CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-12-18 | — | — | US | disclosed |
| EP-2768499-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2709730-A1 | TREATMENT AND PROGNOSIS OF CANCER | Western Connecticut Health Network, Inc. (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2013059245-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20120295932-A1 | METHOD FOR THE TREATMENT OF CANCER | Western Connecticut Health Network, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012158358-A1 | TREATMENT AND PROGNOSIS OF CANCER | Western Connecticut Health Network, Inc. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2010044686-A1 | AKR1C3 AS A BIOMARKER, METHODS OF SELECTING AND TREATING PATIENTS BASED UPON AN AKR1C3 PROFILE AND COMPOUNDS FOR USE THEREIN | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11215617-B2 | Treatment of metastatic prostate cancer | AR, AKR1C3, AKR1C4 | KMT2A 1410/4885MTNR1A 325/4885HTR1A 1940/4885 |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | KMT2A 3904/4885MTNR1A 520/4885HTR1A 3755/4885 |
| US-20230017359-A1 | METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION | AKR1C2, AKR1A1, AKR1B1 | KMT2A 3442/4885MTNR1A 190/4885HTR1A 1969/4885 |
| US-20200041516-A1 | TREATMENT OF METASTATIC PROSTATE CANCER | AR, AKR1C3, AKR1C4 | KMT2A 1410/4885MTNR1A 325/4885HTR1A 1940/4885 |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | KMT2A 3865/4885MTNR1A 426/4885HTR1A 3564/4885 |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | KMT2A 3904/4885MTNR1A 520/4885HTR1A 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.